Comprender su fisiopatología | 20 ABR 20

SARS-CoV-2 y sepsis viral: observaciones e hipótesis

Presumimos que un proceso llamado sepsis viral es crucial para el mecanismo de la enfermedad de COVID-19.
Autor/a: Hui Li, MD, Prof Liang Liu, MD, Prof Dingyu Zhang, MD, Jiuyang Xu, MD, Prof Huaping Dai, MD Nan Tang, PhD  Fuente: The Lancet DOI: SARS-CoV-2 and viral sepsis: observations and hypotheses
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Guan WJ Ni ZY Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; (published online Feb 28.) DOI:10.1056/NEJMoa2002032
  2. Zhang C Shi L Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; (published online March 4.)
  3. Singer M Deutschman CS Seymour CW et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315: 801-810
  4. Zhou F Yu T Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-1062
  5. Lin GL McGinley JP Drysdale SB Pollard AJ. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol. 2018; 92147
  6. Tian S Hu W Niu L Liu H Xu H Xiao S-Y. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020; (published online Feb 28.)  DOI:10.1016/j.jtho.2020.02.010
  7. Xu Z Shi L Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420-422
  8. China National Health Commision. Diagnosis and treatment of novel coronavirus pneumonia in China (trial version 7). Date accessed: April 14, 2020
  9. Yao XH Li TY He ZC et al. A pathological report of three COVID-19 cases by minimally invasive autopsies.
  10. Zhonghua Bing Li Xue Za Zhi. 2020; 49 (in Chinese).: E009
  11. Zhu N Zhang D Wang W Li X et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727-733
  12. Wang W Xu Y Gao R et al. Detection of SARS-CoV-2 in different types of  clinical specimens. JAMA. 2020; (published online March 11.) DOI:10.1001/jama.2020.3786
  13. Zhou P Yang X-L Wang X-G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-273
  14. Hamming I Timens W Bulthuis MLC Lely AT Navis G van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203: 631-637
  15. Jeffers SA Tusell SM Gillim-Ross L et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2004; 101: 15748-15753
  16. Yu WB Tang GD Zhang L Corlett RT. Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data.
  17. Huang C Wang Y Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506
  18. Liu J Li S Liu J et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv. 2020; (published online Feb 22.) (preprint). DOI: 10.1101/2020.02.16.20023671
  19. Iwasaki A Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014; 14: 315-328
  20. Dienz O Rud JG Eaton SM et al. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 2012; 5: 258-266
  21. Russell CD Millar JE Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395: 473-475
  22. Shang L Zhao J Hu Y Du R Cao B. On the use of corticosteroids for 2019- CoV pneumonia. Lancet. 2020; 395: 683-684
  23. Taubenberger JK Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008; 3: 499-522
  24. Gu J Gong E Zhang B et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005; 202: 415-424
  25. Xu X Chen P Wang J et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63: 457-460
  26. Lu R Zhao X Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565-574
  27. Peteranderl C Herold S. the impact of the interferon/tnf-related apoptosis-inducing ligand signaling axis on disease progression in respiratory viral infection and beyond. Front Immunol. 2017; 8: 313
  28. Tang N Li D Wang X Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; (published online Feb 19.) DOI:10.1111/jth.14768
  29. Wang PH Cheng Y. Increasing host cellular receptor—angiotensin-converting enzyme 2 (ace2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv. 2020; (published online Feb 27.) (preprint). DOI: 10.1101/2020.02.24.963348
  30. Sun ML Yang JM Sun YP Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43: 219-222
  31. Ferrario CM Jessup J Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605-2610


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí